



## Arvinas to Participate in Upcoming Virtual Investor Conferences

November 25, 2020

NEW HAVEN, Conn., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming virtual investor conferences:

**Piper Sandler 32nd Annual Virtual Healthcare Conference** on Tuesday, December 1, 2020. A pre-recorded fireside chat held with John Houston, Ph.D., President and Chief Executive Officer, and Ian Taylor, Ph.D., Chief Scientific Officer, is available [here](#) and on the Events + Presentations section of the Company's website.

**3rd Annual Evercore ISI HealthCONx Virtual Conference** on Thursday, December 3, 2020. Ian Taylor, Ph.D., Chief Scientific Officer, and Randy Teel, Ph.D., Vice President of Corporate Development, will participate in a fireside chat at 8:50 a.m. ET. A live audio webcast of the presentation will be available [here](#) and on the Events + Presentations section of the Company's website.

### About Arvinas

Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and "undruggable" targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit [www.arvinas.com](http://www.arvinas.com).

### Contacts for Arvinas

#### Investors

Will O'Connor, Stern Investor Relations  
[ir@arvinas.com](mailto:ir@arvinas.com)

#### Media

Kirsten Owens, Arvinas Communications  
[kirsten.owens@arvinas.com](mailto:kirsten.owens@arvinas.com)